{"disease":{"id":"unknown-primary-tumors","name":"unknown primary tumors"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07524114","title":"Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)","phase":"","overall_status":"RECRUITING","enrollment_count":7000,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT06140992","title":"PaCIFiC-CUP Classifies Cancer of Unknown Primary","phase":"","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05046444","title":"Solving Riddles Through Sequencing","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Munich Leukemia Laboratory","has_results":false},{"nct_id":"NCT06100081","title":"Real-time Targeted Fluorescence Endoscopy for Detection of the Primary Cancer Lesion in Patients With a Metastasis of Unknown Primary Tumor in the Head and Neck","phase":"NA","overall_status":"UNKNOWN","enrollment_count":35,"lead_sponsor_name":"University Medical Center Groningen","has_results":false},{"nct_id":"NCT03418480","title":"HARE-40: HPV Anti-CD40 RNA vaccinE","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"University of Southampton","has_results":false},{"nct_id":"NCT04276597","title":"Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Excel Diagnostics and Nuclear Oncology Center","has_results":false},{"nct_id":"NCT04100694","title":"Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Merus B.V.","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}